纽迪希亚亲舒对便秘婴儿的治疗效果。

Therapeutic effect of Novalac-IT in infants with constipation.

作者信息

Chao Hsun-Chin, Vandenplas Yvan

机构信息

Division of Gastroenterology, Department of Pediatrics, Chang Gung Children's Hospital, Chang Gung Memorial Hospital, Chang Gung University Medical College, Taoyuan, Taiwan.

出版信息

Nutrition. 2007 Jun;23(6):469-73. doi: 10.1016/j.nut.2007.03.006. Epub 2007 Apr 30.

DOI:10.1016/j.nut.2007.03.006

PMID:17467237

Abstract

OBJECTIVE

Infant constipation is a frequent condition in formula-fed infants.

METHODS

A prospective randomized clinical trial was performed in infants who had constipation with Novalac-IT (IT group) versus a 20% strengthened formula (S group). Enrolled subjects had difficulties in defecating, hard stools, or low frequency of defecation (< or =3 times/wk).

RESULTS

Ninety-three infants (47 boys, mean age 3.8 +/- 1.7 mo) were included because of hard consistency of (50.5%), low frequency in (44.1%), or painful (33.3%) defecation. A statistically significant improvement was observed after 4 and 8 wk of intervention in the IT group (P = 0.014 and P < 0.001, respectively). In the IT group, significantly more infants were symptom free at 4 wk (82.9% versus 50%, P = 0.029) and at 8 wk (89.1% versus 54.1%, P < 0.001). Increased stool weight was significant in the IT group after 4 and 8 wk (P = 0.048 and 0.029).

CONCLUSION

Novalac-IT decreases constipation in formula-fed infants.

摘要

目的

婴儿便秘在配方奶喂养的婴儿中是一种常见病症。

方法

对患有便秘的婴儿进行了一项前瞻性随机临床试验，比较了诺优能IT（IT组）与20%强化配方奶（S组）。纳入的受试者存在排便困难、大便干结或排便频率低（≤3次/周）的情况。

结果

93名婴儿（47名男孩，平均年龄3.8±1.7个月）因大便干结（50.5%）、排便频率低（44.1%）或排便疼痛（33.3%）而被纳入研究。在干预4周和8周后，IT组观察到有统计学意义的改善（分别为P = 0.014和P < 0.001）。在IT组中，4周时无症状的婴儿明显更多（82.9%对50%，P = 0.029），8周时也是如此（89.1%对54.1%，P < 0.001）。4周和8周后，IT组的粪便重量增加显著（P = 0.048和0.029）。